CClinicalTrials.gg
Not yet recruitingNCT07708376FASTUpdated Jul 16, 2026

A Registry of the FLOWRUNNER Aspiration System for Patients With Symptomatic Venous Thrombosis

An observational study in Venous Thrombosis Deep (Limbs) and Venous Thrombosis, sponsored by FlowPhysix, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by FlowPhysix, Inc. · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
218
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to evaluate how well and how safe the FLOWRUNNER Aspiration System works for treating blood clots in the arms or legs in real-life medical settings.

Read the detailed description

The study is a registry to collect data from standard of care mechanical thrombectomy procedure using FLOWRUNNER Aspiration System. The FLOWRUNNER Aspiration System is a single use catheter based system indicated for the removal of fresh, soft emboli (a soft clot) and thrombi (a stationary clot) from vessels of the peripheral (in the arms and legs) and venous (blood vessels responsible for carrying deoxygenated blood back to your heart and lungs) system.

02

Conditions studied

  • Venous Thrombosis Deep (Limbs)
  • Venous Thrombosis

Keywords

  • Removal of Symptomatic Venous Thrombosis
  • Symptomatic Venous Thrombosis
  • Thrombosis
  • Thrombectomy
  • Blood Clot
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥ 18 years) undergoing venous thrombectomy with the FLOWRUNNER Aspiration System for acute or sub-acute symptomatic upper- or lower-extremity venous thrombosis.

Eligibility criteria

Eligibility Criteria:

  1. Adults ≥ 18 years of age.
  2. Symptomatic upper- or lower-extremity venous thrombosis.
  3. Treatment with the FLOWRUNNER Aspiration System for venous thrombectomy as part of routine care.
  4. Willing to participate, able to understand and able to voluntarily sign the Informed Consent Form (ICF) prior to the initial qualifying procedure (index procedure).
  5. Willing and able to participate and comply with all protocol-required follow-up visits and assessments.

Exclusion Criteria:

  1. Evidence of a chronic or previously undiagnosed extensive clot on the pre-procedure venogram that makes endovascular thrombectomy inappropriate. Indicators of chronic clot include significant venous narrowing, the presence of diffuse collateral vessels, partial recanalization, Inferior Vena Cava (IVC) hyperplasia, or other congenital anatomic anomalies of the IVC, iliac veins, or subclavian veins.
  2. No available upper- or lower-extremity venous access site suitable for the procedure due to absence of appropriate access, severe anatomical obstruction, scarring, or prior surgical alteration that prevents safe catheter insertion or any condition that, in the investigator's judgement, makes upper- or lower-extremity venous access technically infeasible or unsafe.
  3. Pregnant or breastfeeding at the time of enrollment.
  4. High-risk for pulmonary embolism (PE), defined as those presenting with:

    • Hemodynamic instability (e.g., sustained hypotension, shock, or cardiac arrest)
    • Requirement for thrombolytic therapy or surgical embolectomy
    • Any condition that, in the investigator's judgment, would pose an unacceptable risk for participation in the study
  5. Presents with cardiogenic shock or is hemodynamically unstable.
  6. Any prior or current cancer diagnosis that, in the investigator's judgment, would pose an unacceptable risk or confound study outcomes including but not limited to:

    • Tumor-associated venous thrombosis, defined as: venous thrombosis occurring in the context of active malignancy or cancer-related hypercoagulability
    • Presence of metastatic disease or ongoing chemotherapy
  7. Known antiphospholipid syndrome or other high-risk coagulation disorders, including:

    • Confirmed diagnosis of antiphospholipid antibody syndrome
    • Severe inherited or acquired thrombophilia (e.g., protein C or S deficiency, antithrombin deficiency)
    • Any coagulation disorder that, in the investigator's judgment, would pose an unacceptable risk for thrombectomy or confound study outcomes
  8. Estimated life expectancy of less than 12 months, based on the investigator's clinical judgement, available medical history, and prognostic indicators.
  9. Chronic non-ambulatory status, defined as:

    • Persistent inability to walk or perform basic mobility activities due to underlying medical conditions
    • Conditions such as advanced neurological disease, severe musculoskeletal impairment, or long-term paralysis
  10. Contraindicated for intravascular therapy including:

    • Active bleeding
    • Severe anemia with hemoglobin (Hb) \< 8 g/dL
    • High risk of bleeding
    • History of heparin allergy/hypersensitivity or heparin-induced thrombocytopenia
    • Hypersensitivity to contrast agents
    • Contraindication to oral/intravenous anticoagulation
    • Hypercoagulable risk
    • Any other condition that cannot be effectively managed
  11. Renal dysfunction (eGFR \< 30 mL/min/1.73m2, not yet on dialysis).
  12. Cerebral or myocardial infarction in the last 3 months.
  13. Any condition that, in the investigator's judgment, would pose unacceptable risk or interfere with study participation, including:

    • Severe allergy to contrast media
    • Active systemic infection
    • Uncontrolled coagulopathy
    • Phlegmasia
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
218 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • Symptomatic upper- or lower-extremity venous thrombosis

    The study is an observational registry to collect data on the standard of care treatment of venous thrombosis. There is no investigational intervention. All participants will receive mechanical thrombectomy as standard of care.

    Other: Mechanical Thrombectomy - Standard of Care procedure for venous thrombosis

Interventions

  • OtherMechanical Thrombectomy - Standard of Care procedure for venous thrombosis

    Participant will receive mechanical thrombectomy for venous thrombosis as standard of care. This study is an observational registry to collect data on the standard of care non investigational intervention.

05

What researchers measure

Primary outcomes

  1. Procedure Success

    The number of patients that had a response to treatment after the standard of care mechanical thrombectomy procedure with the study device, defined as removal of thrombus (a large amount of the blood clot from the vein or artery) during the study procedure.

    Time frame: Immediately Post Procedure

  2. Safety Events will measure any risks that may occur during or after the study procedure

    The number of patients that have serious problems after the standard of care mechanical thrombectomy procedure that could be life threatening or cause major harm.

    Time frame: Within 30 days of the study procedure

  3. Procedure Results

    The number of patients that have restoration of flow in the treated vein as measured by X-ray.

    Time frame: Immediately after the study procedure

Secondary outcomes

  1. Vein Patency

    The number of patients that have vein patency as measured by duplex ultrasound or other imaging.

    Time frame: Baseline, 1 Month, 6 Months, 12 Months, 24 Months after the study procedure.

  2. Vein Disability Score

    The number of patients that have improvement in Vein Disability Score which is a clinical assessment by the physician to score how chronic venous disease affects a patient's mobility and daily functionality. A score of 0 means no symptoms and a score of 3 means severe disability. The total score per follow up visit will be compared to baseline.

    Time frame: Baseline, 1 Month, 6 Months, 12 Months, 24 Months after the study procedure

  3. Villalta Score

    The number of patients that have improvement in Villalta Score which is a clinical assessment by the physician to score patient reported symptoms from a score of 0 to 3 based on severity. A score of 0 indicates absence of symptoms and a score of 3 indicates severe symptoms. The total score is the sum of all individual scores. 0-4 is no symptoms to \>15 is severe symptoms. Clinical signs will be scored by the physician or nurse after physical examination of the affected arm/leg.

    Time frame: Baseline, 1 Month, 6 Months, 12 Months, 24 Months after the study procedure

  4. Quality of Life

    The number of patients that have an improvement of Quality of Life as measured by the EuroQol Questionnaire. It evaluates 5 dimensions of health, with 5 levels of severity for each. A score of 1 for each question is good health, a score of 5 for each question is poor health.

    Time frame: Baseline, 1 Month, 6 Months, 12 Months, 24 Months after the study procedure.

Other outcomes

  1. Additional Safety Events

    The number of patients that have serious adverse events (SAEs) will be evaluated.

    Time frame: Up to 24 months after the study procedure

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Rabe E, Hoffmann U, Schimke A, Heinken A, Langer F, Noppeney T, Pittrow D, Klotsche J, Gerlach HE, Bauersachs R; INSIGHTS-SVT Study Collaborators. Determinants of Late Venous Thromboembolic Events After Acute Isolated Superficial Vein Thrombosis in Daily Practice: 12 Month Results of the INSIGHTS-SVT Study. Eur J Vasc Endovasc Surg. 2023 Nov;66(5):697-704. doi: 10.1016/j.ejvs.2023.08.031. Epub 2023 Aug 12. PubMed 37573936 ↗
  • Bauersachs R, Gerlach HE, Heinken A, Hoffmann U, Langer F, Noppeney T, Pittrow D, Klotsche J, Rabe E. Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT). Eur J Vasc Endovasc Surg. 2021 Aug;62(2):241-249. doi: 10.1016/j.ejvs.2021.04.015. Epub 2021 Jun 29. PubMed 34210599 ↗
  • Toma C, Jaber WA, Weinberg MD, Bunte MC, Khandhar S, Stegman B, Gondi S, Chambers J, Amin R, Leung DA, Kado H, Brown MA, Sarosi MG, Bhat AP, Castle J, Savin M, Siskin G, Rosenberg M, Fanola C, Horowitz JM, Pollak JS. Acute outcomes for the full US cohort of the FLASH mechanical thrombectomy registry in pulmonary embolism. EuroIntervention. 2023 Feb 20;18(14):1201-1212. doi: 10.4244/EIJ-D-22-00732. PubMed 36349702 ↗
  • Bisharat MB, Ichinose EJ, Veerina KK, Khetarpaul V, Azene EM, Plotnik AN, Hnath J, Trestman E, Harlin SA, Bhat A, Li S, Long GW, O'Connor D, Winokur RS, Zia S, Dexter DJ. One-Year Clinical Outcomes Following Mechanical Thrombectomy for Deep Vein Thrombosis: A CLOUT Registry Analysis. J Soc Cardiovasc Angiogr Interv. 2024 Feb 15;3(3Part A):101307. doi: 10.1016/j.jscai.2024.101307. eCollection 2024 Mar. PubMed 39131784 ↗
  • Dexter D, Kado H, Shaikh A, Schor J, Annambhotla S, Zybulewski A, Paulisin J, Bisharat M, Mouawad NJ, Bunte MC, Maldonado T, Skripochnik E, Raskin A, Gandhi S, Ichinose E, Beasley R, Mojibian H. Safety and Effectiveness of Mechanical Thrombectomy From the Fully Enrolled Multicenter, Prospective CLOUT Registry. J Soc Cardiovasc Angiogr Interv. 2023 Feb 23;2(2):100585. doi: 10.1016/j.jscai.2023.100585. eCollection 2023 Mar-Apr. PubMed 39129803 ↗
  • Kahn SR. Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome. J Thromb Haemost. 2009 May;7(5):884-8. doi: 10.1111/j.1538-7836.2009.03339.x. Epub 2009 Mar 6. PubMed 19320818 ↗
  • Mittleider D, Gibson CM, Dexter D. Outcomes From Mechanical Thrombectomy for Deep Vein Thrombosis: Insights From the PINC AI Healthcare Database. J Soc Cardiovasc Angiogr Interv. 2024 Jul 25;3(8):102149. doi: 10.1016/j.jscai.2024.102149. eCollection 2024 Aug. PubMed 39166156 ↗
  • Avgerinos ED, Hager ES, Naddaf A, Dillavou E, Singh M, Chaer RA. Outcomes and predictors of failure of thrombolysis for iliofemoral deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2015 Jan;3(1):35-41. doi: 10.1016/j.jvsv.2014.07.007. Epub 2014 Aug 22. PubMed 26993678 ↗
  • Robertson B, Neville E, Muck A, Broering M, Kulwicki A, Kuhn B, Recht M, Muck P. Technical success and short-term results from mechanical thrombectomy for lower extremity iliofemoral deep vein thrombosis using a computer aided mechanical aspiration thrombectomy device. J Vasc Surg Venous Lymphat Disord. 2022 May;10(3):594-601. doi: 10.1016/j.jvsv.2021.11.002. Epub 2021 Nov 23. PubMed 34823046 ↗
  • Lopez R, DeMartino R, Fleming M, Bjarnason H, Neisen M. Aspiration thrombectomy for acute iliofemoral or central deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2019 Mar;7(2):162-168. doi: 10.1016/j.jvsv.2018.09.015. Epub 2019 Jan 10. PubMed 30639411 ↗
  • Enden T, Haig Y, Klow NE, Slagsvold CE, Sandvik L, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012 Jan 7;379(9810):31-8. doi: 10.1016/S0140-6736(11)61753-4. Epub 2011 Dec 13. PubMed 22172244 ↗
  • Haig Y, Enden T, Grotta O, Klow NE, Slagsvold CE, Ghanima W, Sandvik L, Hafsahl G, Holme PA, Holmen LO, Njaaastad AM, Sandbaek G, Sandset PM; CaVenT Study Group. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016 Feb;3(2):e64-71. doi: 10.1016/S2352-3026(15)00248-3. Epub 2016 Jan 6. PubMed 26853645 ↗
  • Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C; ATTRACT Trial Investigators. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med. 2017 Dec 7;377(23):2240-2252. doi: 10.1056/NEJMoa1615066. PubMed 29211671 ↗
  • Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016 Feb;149(2):315-352. doi: 10.1016/j.chest.2015.11.026. Epub 2016 Jan 7. PubMed 26867832 ↗
  • Kohi MP, Kohlbrenner R, Kolli KP, Lehrman E, Taylor AG, Fidelman N. Catheter directed interventions for acute deep vein thrombosis. Cardiovasc Diagn Ther. 2016 Dec;6(6):599-611. doi: 10.21037/cdt.2016.11.20. PubMed 28123980 ↗
  • Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, Gupta DK, Prandoni P, Vedantham S, Walsh ME, Weitz JI; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014 Oct 28;130(18):1636-61. doi: 10.1161/CIR.0000000000000130. Epub 2014 Sep 22. No abstract available. PubMed 25246013 ↗
  • Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, Mohr DN, O'Fallon WM. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc. 2001 Nov;76(11):1102-10. doi: 10.4065/76.11.1102. PubMed 11702898 ↗
  • Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010 Apr;38(4 Suppl):S495-501. doi: 10.1016/j.amepre.2009.12.017. PubMed 20331949 ↗
  • Douma RA, Kamphuisen PW, Buller HR. Acute pulmonary embolism. Part 1: epidemiology and diagnosis. Nat Rev Cardiol. 2010 Oct;7(10):585-96. doi: 10.1038/nrcardio.2010.106. Epub 2010 Jul 20. PubMed 20644564 ↗
  • Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007 Oct;98(4):756-64. doi: 10.1160/TH07-03-0212. PubMed 17938798 ↗
  • White RH. The epidemiology of venous thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I4-8. doi: 10.1161/01.CIR.0000078468.11849.66. PubMed 12814979 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT07708376
Lead sponsor
FlowPhysix, Inc.
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Sep 15, 2028 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Jul 16, 2026

Study contacts

Prasad Nalluri
Contact
prasad.nalluri@flowphysix.com
210-355-9512
Amy Newkirk
Contact
amy.newkirk@flowphysix.com
831-239-6711

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion